Genome & Company acquires US-based List Labs for $27 million
Genome & Company CEO Pae Ji-soo speaks during an online conference, Wednesday. Screenshot from the conferenceKorean biotech firm acquires US-based CDMO firmBy Baek Byung-yeulGenome & Company, Korea's leading microbiome anti-cancer drug developer, is set to expand its business scope to the contract development and manufacturing organization (CDMO) business by acquiring a 60-percent stake in the U.S.-based microbiome CDMO business company, List Labs, for $27 million. The Korean biotech company said Wednesday that it aims to become a leader in both drug development and production through the acquisition.A microbiome refers to the community of microbes ― such as bacteria ― that live in the human body. Thanks to progress in DNA sequencing technologies, microbiomes have turned out to have a huge impact on determining whether people develop various diseases, while scientists and biotech firms are on the way to finding out which bacteria are beneficial and can be developed into treatments“At a time when the microbiome market is expected to see huge growth in the next several ye
